Pictet Asset Management Ltd. boosted its position in shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 14.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 416,780 shares of the biopharmaceutical company’s stock after buying an additional 53,816 shares during the period. Pictet Asset Management Ltd. owned 0.71% of Agios Pharmaceuticals worth $20,789,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Northern Trust Corp increased its position in Agios Pharmaceuticals by 20.5% during the second quarter. Northern Trust Corp now owns 299,654 shares of the biopharmaceutical company’s stock worth $14,947,000 after buying an additional 50,908 shares during the period. Canada Pension Plan Investment Board acquired a new position in Agios Pharmaceuticals during the second quarter worth approximately $1,086,000. Renaissance Technologies LLC acquired a new position in Agios Pharmaceuticals during the second quarter worth approximately $2,509,000. Fosun International Ltd acquired a new position in Agios Pharmaceuticals during the second quarter worth approximately $3,062,000. Finally, Cutler Group LP increased its position in Agios Pharmaceuticals by 26.1% during the second quarter. Cutler Group LP now owns 7,471 shares of the biopharmaceutical company’s stock worth $372,000 after buying an additional 1,546 shares during the period.
Shares of NASDAQ:AGIO traded up $0.05 during trading on Friday, reaching $38.20. The company had a trading volume of 19,781 shares, compared to its average volume of 516,428. The firm has a market capitalization of $2.24 billion, a price-to-earnings ratio of -6.33 and a beta of 2.22. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.96 and a quick ratio of 5.91. The stock’s fifty day moving average price is $40.88 and its 200 day moving average price is $51.45. Agios Pharmaceuticals Inc has a fifty-two week low of $33.17 and a fifty-two week high of $79.17.
A number of research firms have recently issued reports on AGIO. Cowen reissued a “buy” rating on shares of Agios Pharmaceuticals in a report on Friday, May 31st. Goldman Sachs Group reissued a “neutral” rating and issued a $55.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, May 23rd. Zacks Investment Research raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating and set a $46.00 target price on the stock in a report on Wednesday, August 14th. BMO Capital Markets began coverage on Agios Pharmaceuticals in a report on Thursday. They issued an “outperform” rating and a $45.00 target price on the stock. Finally, BidaskClub raised Agios Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday. One analyst has rated the stock with a sell rating, six have given a hold rating and six have assigned a buy rating to the company. Agios Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $68.57.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.
Featured Story: Buyback
Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals Inc (NASDAQ:AGIO).
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.